Axsome Therapeutics (NASDAQ:AXSM) announced Wednesday a settlement agreement with U.K.-based Hikma Pharmaceuticals ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...

AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 ...

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast ...

Hikma Pharmaceuticals PLC HIK shares dropped 6.18% to £21.54 Wednesday, on what proved to be an all-around positive trading ...

Shares in Hikma Pharmaceuticals came under pressure in early trading on Wednesday, despite a jump in annual revenues, after ...

Mercaptopurine oral suspension is indicated for the treatment of patients with acute lymphoblastic leukemia as part of a ...

Amman, Jordan: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the ...

Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn ...

However, Hikma’s core EBIT for the year stood at $719 million, with a margin of 22.8%, slightly below the consensus estimate of 23.4%. Hikma’s 2H24 results showed a 3% sales beat, primarily driven by ...

(Alliance News) - Hikma Pharmaceuticals PLC on Wednesday said it planned to increased spending on research and development to support further growth after reporting strong annual results. The ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by ...